Core Capital Partners (formerly Hamza Thindal Capital Corp.) has been involved with Vanc Pharmaceuticals since 2012, with an initial co-investment of $800,000 and now an aggregate investment of $4.3MM over the past 24 months. Vanc is a Vancouver, BC based generic drug and OTC products company. The Company has partnered with global generics pharmaceuticals manufactures to provide Canadians with high quality and affordable generic drugs and OTC products.
The Company is lead by Mr. Arun Nayyar, an international generic pharmaceuticals executive with over 30 years of experience and a track record of achieving market penetration, sales channel development, product in-licensing and regulatory registration.
Vanc currently has a generic portfolio consisting of over 30 molecules, which represent both chronic and acute conditions. The Company also has four niche market OTC products covering the iron supplement (Feroheme), pediatric drops (Pedia-Safe), a natural laxative (Sennna-Lax) and cortisone ointment (T36 + 0.5% Hydrocortisone). The Company plans to launch sales in Q2-2015 and in February 2015 announced a LOI with a Western Canada based pharmacy chain to become a preferred supplier.